Biotech company Efferon has secured €2.5 million in a seed funding round led by private investors from the DACH region. This capital infusion will support the European commercial expansion of Efferon LPS, a hemoadsorption device already used in over 25,000 treatments across 40 countries for sepsis and septic shock. The funds will specifically finance the construction of a new EU production facility and increase manufacturing capacity.